Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration

Ophthalmic Epidemiology

Volumn 21, Issue 6, 2014, Pages 347-355

  Van Asten, Freekje ^a   Rovers, Maroeska M ^a   Lechanteur, Yara T E ^a   Smailhodzic, Dzenita ^a   Muether, Philipp S ^b   Chen, John ^c   Den Hollander, Anneke I ^a   Fauser, Sascha ^b   Hoyng, Carel B ^a   Van Der Wilt, Gert Jan ^a   Jeroen Klevering, B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Age related macular degeneration; Anti VEGF treatment; Non response; Prediction model; Response prediction

Indexed keywords

RANIBIZUMAB; ARMS2 PROTEIN, HUMAN; CFH-CFHL1 PROTEIN, HUMAN; CHIMERIC PROTEIN; COMPLEMENT FACTOR H; MONOCLONAL ANTIBODY; PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; ALLELE; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY; VISUAL ACUITY; WET MACULAR DEGENERATION; CAUCASIAN; CLINICAL TRIAL; GENETICS; GENOTYPE; MACULAR DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; RETINAL NEOVASCULARIZATION; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COMPLEMENT FACTOR H; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; MACULAR DEGENERATION; MALE; MUTANT CHIMERIC PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; RETINAL NEOVASCULARIZATION; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84911459474     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.3109/09286586.2014.949010     Document Type: Article

References (30)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-572.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99(6):933-943.
3. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108(4):697-704.
4. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115(1):116-126.
5. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med 2006;355(14):1432-1444.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006;355(14):1419-1431.
7. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65 e5.
8. Macular Photocoagulation Study Group. Subfoveal neo-vascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991;109(9): 1242-1257.
9. Tian J, Qin X, Fang K, et al. Association of genetic polymorphisms with response to bevacizumab for neo-vascular age-related macular degeneration in the Chinese population. Pharmacogenomics 2012;13(7):779-787.
10. Yamashiro K, Tomita K, Tsujikawa A, et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012;154(1):125-136.
11. Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmolog 2011;89(4):e344-349.
12. Brantley Jr MA, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114(12): 2168-2173.
13. Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009;93(5):610-613.
14. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizu-mab in patients with neovascular AMD. Investig Ophthalmol Vis Sci 2011;52(7):4694-4702.
15. Teper SJ, Nowinska A, Pilat J, et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010;16:2598-2604.
16. McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96(2):208-212.
17. Smailhodzic D, Muether PS, Chen J, et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012;119(11): 2304-2311.
18. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(2): 246-252.
19. Menghini M, Kurz-Levin MM, Amstutz C, et al. Response to ranibizumab therapy in neovascular AMD-an evaluation of good and bad responders. Klin Monatsblatter Augenheilkunde 2010;227(4):244-248.
20. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144(6):850-857.
21. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bev-acizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120(1):122-129.
22. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nature Meth 2012;9(7):676-682.
23. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med 1996;15(4):361-387.
24. Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. Br Med J 2009;338:1373-1377.
25. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. Br Med J 2009;338:1432-1435.
26. Steyerberg EW, Eijkemans MJ, Harrell Jr FE, Habbema JD. Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Decis Making 2001;21(1):45-56.
27. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111(7): 1280-1287.
28. Klein R, Klein BE, Moss SE. Diabetes, hyperglycemia, and age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99(10):1527-1534.
29. Byun YJ, Lee SJ, Koh HJ. Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Japan J Ophthalmol 2010; 54(6):571-577.
30. Singh RP, Fu EX, Smith SD, et al. Predictive factors of visual and anatomical outcome after intravitreal bevacizu-mab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. Br J Ophthalmol 2009;93(10):1353-1358.